Bakshi and co-authors [23] evaluated the putative role of uric acid as a candidate biomarker of PD risk modulation in pathogenic LRRK2 mutation carriers using data from the LRRK2 Cohort Consortium and the PPMI. The gene discussed is LRRK2; the disease is Parkinson disease.